1.Influence ofSheng-Huangmixture oncardiocyte apoptosis and bax and bcl-2 mRNA expression in a rat model of ischemia-reperfusion injury
Chinese Journal of Tissue Engineering Research 2016;20(27):4049-4054
BACKGROUND:Sheng-Huangmixture includingChinese medicine Shengmai Decoction and total flavonoids of stems and leaves of radix has been shown to resist inflammation, regulate immune function, and protect ischemic myocardial tissues. However, its effect on the apoptosis of cardiac muscle cels after ischemia/reperfusion injury remains unclear.
OBJECTIVE:To investigate the effects ofSheng-Huangmixture on cardiocyte apoptosis and bax and bcl-2 mRNA expression in rats with ischemia-reperfusion injury.
METHODS:Thirty-six Sprague-Dawley rats weredivided randomly into six groups: low-dose, moderate-dose and high-doseSheng-Huangmixture, positive control, blank and model groups (n=6). After 7 days of administration, models of myocardial ischemia-reperfusion injury were established. TUNEL was usedto detect myocardial apoptosis. RT-PCR was utilized to measure bax and bcl-2 mRNA expression in the ischemic and reperfusion region.
RESULTS AND CONCLUSION:(1) The bcl-2 mRNA expression was significantly higher in the Sheng-Huangmixture group than in the model group (P< 0.05), but bax mRNA expression was significantly lower (P< 0.05). Thus, bcl-2/bax ratio increased. In addition, apoptosis index was more significantly decreased in theSheng-Huangmixture group(P< 0.05). (2) Results demonstrated that Sheng-Huangmixture can protect rat myocardium against ischemia/reperfusion injury, and effectively increase the bcl-2/bax ratio andinhibit the apoptosis of cardiomyocytes, and the underlying mechanism is mediated by up-regulating bcl-2 mRNA expression and down-regulating bax mRNA expression.
2.Detection of Synthetic Pigments in Chinese Patent Drugs by Solid Phase Extraction-HPLC
China Pharmacist 2014;(2):201-204
Objective:To establish a method for detecting synthetic pigments in Chinese patent drugs by solid phase extraction-HPLC(SPE-HPLC). Methods:Purified with SPE and concentrated, the sample was separated on a SHISEIDO C18 column with 0. 02 mol·L-1 ammonium acetate and methanol mixed solution as the mobile phase with gradient elution at the flow rate of 1. 0 ml·min-1 , the detection wavelength of 508nm, column temperature of 30℃,and the injection volume of 10μl. Results: The linear range of the synthetic pigments was 0. 005-0. 200 μg(r=0. 999 9), and the average recovery was 97. 6%(RSD=1. 3%,n=6),97. 0%(RSD=1. 4%,n=6) and 99. 5%(RSD=1. 4%,n=6), respectively. Conclusion:The proposed method is simple, reliable and reproduci-ble, and especially suitable for the detection of synthetic pigments in Chinese patent drugs.
3.Treatment of drug eruption of epidermolysis bullosa with high-power photon therapeutic device in one case
China Medical Equipment 2009;(8):44-45
We routinely used the high-power photon therapeutic device to treat drug eruption of epidermolysis bullosa in 1 case and there achieved good results.Through analysis,we believe that the device can be used to treat different types of complicated skin diseases.
4.The effect of non-restrictive external stent on cell proliferation in rabbit vein grafts
Medical Journal of Chinese People's Liberation Army 2001;0(12):-
Objective To investigate the effect of non-restrictive external stent on both cell proliferation of rabbit vein grafts and prevention from hyperplasia of the grafts' neointima. Methods 36 New Zealand white rabbits were randomly divided into two groups, each animal was subjected to a reversed autologous venous graft between external jugular vein and common carotid artery. In stenting group (group S), the vein grafts were surrounded by a 6 mm in diameter non-restrictive stent, and in non-stenting group (group NS), there is no stent to support the vein grafts. The grafts were harvested 1 week (1W), 2 weeks (2W) and 4 weeks (4W) after surgery, respectively. The sections were stained with hematoxylin and eosin stain, ?-smooth muscle actin (?-SMA) and proliferating cell nuclear antigen (PCNA) immunocytochemistry stain. PCNA index was calculated in intima, media and adventitia, respectively. Results (1) HE staining: From 1W to 4W, the hyperplasia of intima and media appeared gradually in both group S and group NS, nevertheless such hyperplasia in group S was lessintense than in group NS. (2) ?-SMA staining: Almost all cells in media were positive, but few cells were positive in intima of both groups at 1W; the thickness of intima of both groups increased gradually, and almost all cells except endothelial cells were positive in intima in both groups, though the thickness of intima of group S was smaller than in group NS at 2W and 4W. (3) PCNA index: the index of intima in both two groups peaked at 2W, and the index of intima in group S was less than in group NS at 2W and 4W, P
5.The role of cardiac renin-angiotensin system in the development of volume-overload myocardial hypertrophy in rats
Chinese Journal of Pathophysiology 1986;0(02):-
The present study was performed to determine whether or not that cardiacrenin-angiotensin system (RAS) plays an important role in volume-overload myocardialhypertrophy. In order to control the increase of circulating RAS, aortacava fistula withnephrectomy (ACF+NT) rats were used in the experiment. The ventricular angiotensin Ⅰ,Ⅱ (Ang Ⅰ,Ⅱ) contents and angiotensin-converting enzyme (ACE) activities were measuredby means of radioimmunoassay and biochemical method. It was shown that in ACF+NTrats, the Ang Ⅱ contents and ACE activities in both left and right ventricles increasedsignificantly despite the plasma Ang Ⅰ, Ⅱ and renin activity remained at a lower level.These results indicate that: (1) Cardiac RAS as a relatively independent system, plays aregulatory role in the development of volume-overload cardiac hypertrophy; (2) The in-crease of Ang Ⅱ content was partly caused by the enhancement of ACE activities; (3) Atleast at the early stage of volume-overload cardiac hypertrophy, the circulating RAS maynot be a necessary promoter.
6.Comparison of laparoscopic assisted small incision in the neck surgery and traditional open surgical treatment of benign thyroid
Chinese Journal of Primary Medicine and Pharmacy 2014;(21):3220-3221,3222
Objective To compare the neck incision laparoscopic assisted surgery and conventional open surgical treatment of thyroid benign clinical efficacy,and explore the small incision endoscopic assisted neck safety and effectiveness.Methods According to a random number table,100 patients with benign thyroid were randomly divided into the control group and observation group,50 cases in each group.The patients in the observation group were underwent endoscopic assisted small incision neck surgery,and the patients in the control group of traditional open surgery.The efficacy of postoperative of the two groups was observed and compared.Results The operative time,hospitalization time,blood loss,drainage,drainage time of the observation group was (57.4 ±11.7)min,(3.2 ± 1.0)d,(9.4 ±5.2)mL,(21.4 ±13.5)mL,(1.7 ±0.8)d,which were better than those of the control group(t=8.577,6.352,17.563,12.970,6.273,all P<0.05);The overall incidence of complications in the observation group after the treatment was 8%,which was significantly lower than 30% in the control group(χ2 =7.86,P<0.05). Conclusion Endoscopic surgery assisted small incision in the neck benign thyroid is superior to traditional open sur-gery,and is a simple,effective and safe surgical approach.Compared to traditional open surgery,it has better cosmetic results,which is worthy of clinical application.
7.An early stage morphologic analysis for non-restrictive external stent to prevent vein graft failure
Chinese Journal of Thoracic and Cardiovascular Surgery 2003;0(03):-
0.05; at 14 d,28 d, the thickness and area of the intiam in group S were smaller than those in group NS,P
8.The expression of integrin ?_(1) and its prognostic significance in osteosarcoma
Journal of Third Military Medical University 2003;0(18):-
Objective To investigate the expression of integrin ?_(1) in human osteosarcoma_()and its relationship to prognosis.Methods The expression of integrin ?_(1)was measured by immunohistochemistry and its relationship to prognosis was analyzed statistically.Results Twenty-five of 34 osteosarcoma specimens were found positive staining of integrin ?_(1)(73.5%).The expression levels of integrin ?_(1)was not related to Dahlin classification of osteosarcoma,age and sex,but significantly increased in the osteoblast type and was related to poor survival.Conclusion Integrin ?_(1) can serve as a new biological indicator for the prognosis in osteosarcoma.
9.Primary anaplastic large cell lymphoma of lung: report of a case.
Chinese Journal of Pathology 2012;41(5):345-346
Adult
;
Carcinoma, Neuroendocrine
;
metabolism
;
pathology
;
Diagnosis, Differential
;
Female
;
Hodgkin Disease
;
metabolism
;
pathology
;
Humans
;
Ki-1 Antigen
;
metabolism
;
Leukocyte Common Antigens
;
metabolism
;
Lung Neoplasms
;
metabolism
;
pathology
;
surgery
;
Lymphoma, Large B-Cell, Diffuse
;
metabolism
;
pathology
;
Lymphoma, Large-Cell, Anaplastic
;
metabolism
;
pathology
;
surgery
;
Melanoma
;
metabolism
;
pathology
;
Mucin-1
;
metabolism
;
Pneumonectomy
;
Poly(A)-Binding Proteins
;
metabolism
;
Receptor Protein-Tyrosine Kinases
;
metabolism
;
T-Cell Intracellular Antigen-1
10.Advances in molecular targeted therapy for soft tissue sarcomas
Tian GAO ; Zhengfu FAN ; Zhiwei FANG
Chinese Journal of Clinical Oncology 2017;44(1):7-13
Sarcomas are tumors of mesenchymal origin that account for approximately 1%of human cancers. There are at least 60 dif-ferent subtypes of soft tissue sarcoma (STS). However, most tumor types are highly malignant tumors that lack an optimal therapeutic agent. Although gastrointestinal stromal tumor (GIST) responds well to imatinib, other types of STSs remain challenging because of their heterogeneous genetic and clinical features and poor prognosis. In recent years, the field of molecular targeted therapy has pro-gressed rapidly. Patients with advanced disease can receive individualized treatment to improve their quality of life. This review focus-es on the targeted therapies that have been evaluated for advanced non-GIST STS. Other promising novel therapeutic agents that are currently in the early phases of investigation are also presented.